UBS Group’s Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021 PHIOW Stock Holding History

UBS Group’s Portfolio PHIOW Stock Details PHIOW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,664	Closed	–	–	11265
2021 Q3	$0	Buy	+1,664	New	+$289	﹤0.01%	10614
2021 Q2	–	Sell	-17,722	Closed	-$5K	–	10215
2021 Q1	$5K	Buy	17,722 +16,823	+1,871%	+$5.86K	﹤0.01%	8375
2020 Q4	$0	Buy	+899	New	+$136	﹤0.01%	8990
2020 Q2	–	Sell	-220	Closed	–	–	8563
2020 Q1	$0	Sell	220 -2,853	-93%	-$89	﹤0.01%	8631
2019 Q4	$0	Sell	3,073 -505	-14%	-$28	﹤0.01%	8575
2019 Q3	$0	Hold	3,578	–	–	﹤0.01%	8412
2019 Q2	$0	Hold	3,578	–	–	﹤0.01%	8319
2019 Q1	$0	Buy	3,578 +200	+6%	+$7	﹤0.01%	8383
2018 Q4	$0	Buy	+3,378	New	+$135	﹤0.01%	8451

UBS Group's PHIOW Position: Q4 2021 in Review

UBS Group sold out of Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021 (PHIOW) in Q4 2021, closing a stake of 1,664 shares.

UBS Group first reported a position in PHIOW in Q4 2018 and held it in 9 quarters. The position peaked at $5K in Q1 2021. 0 funds tracked by Wall St. Rank hold PHIOW as of Q4 2021.

UBS Group reported no remaining Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021 position as of Q4 2021 after selling out during the quarter.
UBS Group sold 1,664 Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021 shares in Q4 2021.
UBS Group first reported a position in Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021 in Q4 2018 and held it in 9 quarters.
UBS Group's Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021 position peaked at $5K in Q1 2021.
0 funds tracked by Wall St. Rank held Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021 as of Q4 2021.

Based on UBS Group's 13F filing for Q4 2021, filed 14 Feb 2022.